MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MediWound (Nasdaq: MDWD), a pioneer in enzymatic therapeutics for tissue repair, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Ofer Gonen will engage in a fireside chat on February 12, 2025, at 8:00 AM ET, moderated by Francois Brisebois, Managing Director and Senior Biotechnology Research Analyst at Oppenheimer.
The virtual event will be accessible through registration, and a webcast link will be available on MediWound's website under the Events & Presentations section. The management team will also conduct one-on-one meetings with investors during the conference, which can be arranged through Oppenheimer representatives.
MediWound (Nasdaq: MDWD), un pioniere nelle terapie enzimatiche per la riparazione dei tessuti, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Salute di Oppenheimer. Il CEO Ofer Gonen parteciperà a una chiacchierata informale il 12 febbraio 2025, alle 8:00 ET, moderata da Francois Brisebois, Direttore Generale e Analista Senior di Ricerca in Biotecnologia di Oppenheimer.
L'evento virtuale sarà accessibile previa registrazione, e un link per la trasmissione sarà disponibile sul sito di MediWound nella sezione Eventi e Presentazioni. Il team di gestione condurrà anche incontri individuali con gli investitori durante la conferenza, che possono essere organizzati attraverso i rappresentanti di Oppenheimer.
MediWound (Nasdaq: MDWD), un pionero en terapias enzimáticas para la reparación de tejidos, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. El CEO Ofer Gonen participará en una charla informal el 12 de febrero de 2025, a las 8:00 AM ET, moderada por Francois Brisebois, Director General y Analista Senior de Investigación en Biotecnología de Oppenheimer.
El evento virtual será accesible mediante registro, y un enlace para la transmisión estará disponible en el sitio web de MediWound en la sección de Eventos y Presentaciones. El equipo de gestión también llevará a cabo reuniones individuales con inversores durante la conferencia, que se pueden organizar a través de los representantes de Oppenheimer.
MediWound (Nasdaq: MDWD)는 조직 수리를 위한 효소 치료의 선구자로, Oppenheimer 제35회 연례 건강 생명 과학 회의에 참여한다고 발표했습니다. CEO Ofer Gonen은 2025년 2월 12일 오전 8시 ET에 Francois Brisebois가 진행하는 화상 채팅에 참여할 예정입니다. Brisebois는 Oppenheimer의 생명공학 연구 분석의 관리 이사이기도 합니다.
이번 가상 이벤트는 등록을 통해 접근할 수 있으며, MediWound 웹사이트의 이벤트 및 발표 섹션에서 웹캐스트 링크를 확인할 수 있습니다. 경영팀은 또한 회의 동안 투자자와의 일대일 회의를 진행하며, 이는 Oppenheimer 대표를 통해 조정할 수 있습니다.
MediWound (Nasdaq: MDWD), un pionnier dans les thérapies enzymatiques pour la réparation des tissus, a annoncé sa participation à la 35ème Conférence Annuelle sur les Sciences de la Vie et de la Santé d'Oppenheimer. Le PDG Ofer Gonen participera à une discussion informelle le 12 février 2025 à 8h00 ET, animée par Francois Brisebois, Directeur Général et Analyste Senior en Recherche Biotechnologique chez Oppenheimer.
L'événement virtuel sera accessible sur inscription, et un lien pour la diffusion sera disponible sur le site Web de MediWound dans la section Événements et Présentations. L'équipe de direction organisera également des réunions individuelles avec les investisseurs durant la conférence, qui peuvent être organisées par l'intermédiaire des représentants d'Oppenheimer.
MediWound (Nasdaq: MDWD), ein Pionier in enzymatischen Therapien zur Gewebereparatur, hat seine Teilnahme an der 35. Jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer bekanntgegeben. CEO Ofer Gonen wird am 12. Februar 2025 um 8:00 Uhr ET an einem informellen Gespräch teilnehmen, das von Francois Brisebois, dem Geschäftsführer und leitenden Biotechnologieforschungsanalysten bei Oppenheimer, moderiert wird.
Die virtuelle Veranstaltung wird nach Registrierung zugänglich sein, und ein Webcast-Link wird auf der Website von MediWound im Bereich Veranstaltungen und Präsentationen verfügbar sein. Das Management-Team wird während der Konferenz auch persönliche Meetings mit Investoren durchführen, die über die Vertreter von Oppenheimer arrangiert werden können.
- None.
- None.
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend the virtual fireside chat, please register here.
A webcast link to access the fireside chat will also be posted to MediWound’s website on the Events & Presentations page of the Investors section.
In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their Oppenheimer representative to schedule a meeting.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available
For more information visit www.mediwound.com and follow us on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| +1-929-588-2008 | |
FAQ
When is MediWound (MDWD) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access MDWD's fireside chat at the Oppenheimer Conference?
Will MDWD management be available for individual investor meetings at the Oppenheimer Conference?
Who will be moderating MDWD's fireside chat at the Oppenheimer Healthcare Conference?
